Condition

Diabetic Macular Edema (DME)

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 15 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15
Recruiting6
Common interventions25
Lead sponsors shown14
Advertisement

Clinical trials

15 shown
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaNCT07812090 · 2026-08-21
RECRUITING
Corticosteroid for Diabetic Macular Edema (DME) StudyNCT07843849 · 2026-04-07
RECRUITING
Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar RanibizumabNCT07520045 · 2026-03-12
RECRUITING
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous VitrectomyNCT06662994 · 2025-07-07
RECRUITING
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South WalesNCT06914778 · 2025-03-31
RECRUITING
Impact of Intravitreal Faricimab on Renal Function in Diabetic PatientsNCT06929507 · 2025-03-10
RECRUITING
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)NCT07842016 · 2026-10-15
NOT_YET_RECRUITING
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)NCT07841899 · 2026-10-15
NOT_YET_RECRUITING
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsNCT07456826 · 2026-03-31
ENROLLING_BY_INVITATION
Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract SurgeryNCT07301775 · 2026-01-01
NOT_YET_RECRUITING
AI Prediction of Treatment Response in DMENCT07707856 · 2025-05-15
COMPLETED
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World SettingNCT06398080 · 2024-12-12
WITHDRAWN
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)NCT04857996 · 2021-06-25
COMPLETED
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular EdemaNCT04697758 · 2020-12-10
TERMINATED
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease PreventionNCT03859245 · 2019-02-23
UNKNOWN

Common interventions

Trial status mix

RECRUITING6
NOT_YET_RECRUITING3
COMPLETED2
ENROLLING_BY_INVITATION1
TERMINATED1
UNKNOWN1
WITHDRAWN1

Phase mix

PHASE44
NA3
PHASE23
PHASE32
PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.